These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 33404008)

  • 1. Dose-related treatment outcomes in South African patients prescribed clofazimine for drug-resistant tuberculosis.
    Misra N; Padayatchi N; Naidoo P
    S Afr Med J; 2020 Dec; 111(1):61-67. PubMed ID: 33404008
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-related adverse events in South African patients prescribed clofazimine for drug-resistant tuberculosis.
    Misra N; Padayatchi N; Naidoo P
    S Afr Med J; 2019 Dec; 110(1):32-37. PubMed ID: 31865940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies.
    Hwang TJ; Dotsenko S; Jafarov A; Weyer K; Falzon D; Lunte K; Nunn P; Jaramillo E; Keshavjee S; Wares DF
    BMJ Open; 2014 Jan; 4(1):e004143. PubMed ID: 24384902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review of clofazimine for the treatment of drug-resistant tuberculosis.
    Gopal M; Padayatchi N; Metcalfe JZ; O'Donnell MR
    Int J Tuberc Lung Dis; 2013 Aug; 17(8):1001-7. PubMed ID: 23541151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clofazimine in the treatment of extensively drug-resistant tuberculosis with HIV coinfection in South Africa: a retrospective cohort study.
    Padayatchi N; Gopal M; Naidoo R; Werner L; Naidoo K; Master I; O'Donnell MR
    J Antimicrob Chemother; 2014 Nov; 69(11):3103-7. PubMed ID: 24986495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic interaction between bedaquiline and clofazimine in patients with drug-resistant tuberculosis.
    Maartens G; Brill MJE; Pandie M; Svensson EM
    Int J Tuberc Lung Dis; 2018 Jan; 22(1):26-29. PubMed ID: 29145924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen.
    Ndjeka N; Schnippel K; Master I; Meintjes G; Maartens G; Romero R; Padanilam X; Enwerem M; Chotoo S; Singh N; Hughes J; Variava E; Ferreira H; Te Riele J; Ismail N; Mohr E; Bantubani N; Conradie F
    Eur Respir J; 2018 Dec; 52(6):. PubMed ID: 30361246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis.
    Liu Y; Gao J; Du J; Shu W; Wang L; Wang Y; Xue Z; Li L; Xu S; Pang Y
    Int J Infect Dis; 2021 Jan; 102():392-396. PubMed ID: 33130209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil.
    Dalcolmo M; Gayoso R; Sotgiu G; D'Ambrosio L; Rocha JL; Borga L; Fandinho F; Braga JU; Galesi VM; Barreira D; Sanchez DA; Dockhorn F; Centis R; Caminero JA; Migliori GB
    Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28331044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linezolid-containing regimens for the treatment of drug-resistant tuberculosis in South African children.
    Rose PC; Hallbauer UM; Seddon JA; Hesseling AC; Schaaf HS
    Int J Tuberc Lung Dis; 2012 Dec; 16(12):1588-93. PubMed ID: 23032215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clofazimine for the treatment of multidrug-resistant tuberculosis: prospective, multicenter, randomized controlled study in China.
    Tang S; Yao L; Hao X; Liu Y; Zeng L; Liu G; Li M; Li F; Wu M; Zhu Y; Sun H; Gu J; Wang X; Zhang Z
    Clin Infect Dis; 2015 May; 60(9):1361-7. PubMed ID: 25605283
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QT Interval Prolongation with One or More QT-Prolonging Agents Used as Part of a Multidrug Regimen for Rifampicin-Resistant Tuberculosis Treatment: Findings from Two Pediatric Studies.
    Ali AM; Radtke KK; Hesseling AC; Winckler J; Schaaf HS; Draper HR; Solans BP; van der Laan L; Hughes J; Fourie B; Nielsen J; Garcia-Prats AJ; Savic RM
    Antimicrob Agents Chemother; 2023 Jul; 67(7):e0144822. PubMed ID: 37358463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multidisciplinary management of difficult-to-treat drug resistant tuberculosis: a review of cases presented to the national consilium in Uganda.
    Baluku JB; Katuramu R; Naloka J; Kizito E; Nabwana M; Bongomin F
    BMC Pulm Med; 2021 Jul; 21(1):220. PubMed ID: 34246234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clofazimine in the treatment of multidrug-resistant tuberculosis.
    Xu HB; Jiang RH; Xiao HP
    Clin Microbiol Infect; 2012 Nov; 18(11):1104-10. PubMed ID: 22192631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis.
    Dey T; Brigden G; Cox H; Shubber Z; Cooke G; Ford N
    J Antimicrob Chemother; 2013 Feb; 68(2):284-93. PubMed ID: 23054996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of isoniazid resistance-conferring mutations associated with multidrug-resistant tuberculosis in Free State Province, South Africa.
    Pitso L; Potgieter S; Van der Spoel van Dijk A
    S Afr Med J; 2019 Aug; 109(9):659-664. PubMed ID: 31635590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients.
    Ardhianto D; Suharjono ; Soedarsono ; Fatmawati U
    J Basic Clin Physiol Pharmacol; 2021 Jun; 32(4):421-427. PubMed ID: 34214323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adverse events during treatment of drug-resistant tuberculosis: a comparison between patients with or without human immunodeficiency virus co-infection.
    Sagwa E; Ruswa N; Musasa JP; Mantel-Teeuwisse AK
    Drug Saf; 2013 Nov; 36(11):1087-96. PubMed ID: 23917883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Access to new drugs and the global drug-resistant TB crisis: a case series from KwaZulu-Natal, South Africa.
    Master I; Furin J
    Int J Tuberc Lung Dis; 2016 Jul; 20(7):985-7. PubMed ID: 27287655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severe adverse events during second-line tuberculosis treatment in the context of high HIV Co-infection in South Africa: a retrospective cohort study.
    Schnippel K; Berhanu RH; Black A; Firnhaber C; Maitisa N; Evans D; Sinanovic E
    BMC Infect Dis; 2016 Oct; 16(1):593. PubMed ID: 27769174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.